SFO
TARO

Standard Family Office’s Taro Pharmaceutical Industries Ltd. TARO Stock Holding History

Standard Family Office’s Portfolio TARO Stock Details TARO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-55
Closed -$2K – 474
2022
Q3 		$2K Hold
55
– – ﹤0.01% 429
2022
Q2 		$2K Buy
+55
New +$2.1K 0.02% 185
2022
Q1 		– Sell
-67
Closed -$3K – 255
2021
Q4 		$3K Buy
+67
New +$3.75K 0.03% 179
2021
Q2 		– Sell
-245
Closed -$18K – 645
2021
Q1 		$18K Hold
245
– – ﹤0.01% 296
2020
Q4 		$18K Buy
+245
New +$15.7K ﹤0.01% 293

Other funds holding TARO

KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Standard Family Office's TARO Position: Q4 2022 in Review

Standard Family Office sold out of Taro Pharmaceutical Industries Ltd. (TARO) in Q4 2022, closing a stake of 55 shares — an estimated $2K sold.

Standard Family Office first reported a position in TARO in Q4 2020 and held it in 5 quarters. The position peaked at $18K in Q1 2021. 62 funds tracked by Wall St. Rank hold TARO as of Q4 2022.

  • Standard Family Office reported no remaining Taro Pharmaceutical Industries Ltd. position as of Q4 2022 after selling out during the quarter.
  • Standard Family Office sold 55 Taro Pharmaceutical Industries Ltd. shares in Q4 2022, an estimated $2K.
  • Standard Family Office first reported a position in Taro Pharmaceutical Industries Ltd. in Q4 2020 and held it in 5 quarters.
  • Standard Family Office's Taro Pharmaceutical Industries Ltd. position peaked at $18K in Q1 2021.
  • 62 funds tracked by Wall St. Rank held Taro Pharmaceutical Industries Ltd. as of Q4 2022.

Based on Standard Family Office's 13F filing for Q4 2022, filed 13 Feb 2023.